glp-1 receptor agonist function agonists show promise in treating substance use disorders GLP-1 receptor agonists and next-generation

Linge J, Birkenfeld AL, Neeland IJ

It also slows the emptying of the stomach, enhancing the sensation of fullness after meals

Putting orforglipron in context Because obesity therapies are evolving rapidly in a market dominated by injectables since semaglutides weight-loss approval in 2021, it is helpful to view orforglipron alongside established and emerging incretin-based drugs

Ive been taking them together for about 6 months and Im down 12 pounds without doing anything extreme

Int J Stroke

Patients with established cardiovascular disease should receive a pharmacological treatment intensification with an agent that has demonstrated benefit in cardiovascular safety studies: In patients with pre-existing atherosclerotic cardiovascular disease (ASCVD), a GLP-1 receptor agonist, or SGLT-2 inhibitor with characterized cardiovascular safety should be used